ITeos Therapeutics
iTeos Therapeutics specializes in targeted immunotherapies for cancer, leveraging a deep understanding of the tumor microenvironment and immunosuppressive pathways. The company has two clinical-stage programs, EOS-448 and Inupadenant, designed to offer best-in-class properties and is committed to integrating ESG principles into its operations.
Company Overview of ITeos Therapeutics
iTeos Therapeutics, founded in 2013, specializes in targeted immunotherapies for cancer patients. It leverages a deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates. The company operates from its headquarters in Watertown, Massachusetts, along with a research center in Gosselies, Belgium. With a team of over a hundred employees, iTeos Therapeutics is recognized for its contribution to the next-generation cancer immunotherapies.
ITeos Therapeutics Products
ITeos Therapeutics has developed two clinical-stage programs, EOS-448 and Inupadenant. EOS-448 is an anti-TIGIT human immunoglobulin G1 antibody designed to inhibit TIGIT's immunosuppressive activity, activating the FcγR on macrophages, dendritic cells, and NK cells. Inupadenant targets the ATP-adenosine pathway, specifically inhibiting the A2AR, and remains potent at high adenosine concentrations. Both drugs are evaluated for safety, tolerability, and anti-tumor activity, in monotherapy or in combination with additional drugs like pembrolizumab and chemotherapy.
ESG Commitment at ITeos Therapeutics
ITeos Therapeutics is committed to integrating Environmental, Social, and Governance (ESG) principles into its operations. This commitment underscores their approach to corporate responsibility and ethical business practices. By incorporating ESG considerations, iTeos aims to create sustainable value for stakeholders while addressing broader societal impacts.
Clinical Trials and Research Programs at ITeos Therapeutics
iTeos Therapeutics conducts clinical trials through five phases: Discovery, Preclinical, Phase 1, Phase 2, and Phase 3. EOS-448 is being tested in combination with pembrolizumab for advanced solid tumors and with iberdomide and dexamethasone for multiple myeloma. Inupadenant is evaluated as a monotherapy and in combinations, including pembrolizumab and chemotherapy, for treating solid tumors. These trials assess the safety, tolerability, and effectiveness of these drugs in cancer therapy.
Collaborations of ITeos Therapeutics
iTeos Therapeutics collaborates with various pharmaceutical entities to advance its drug candidates. Notably, EOS-448 is co-developed and co-commercialized with GSK. This collaboration aims to leverage combined expertise to bring effective cancer immunotherapies to the market. These partnerships play a critical role in the development and potential success of iTeos Therapeutics' targeted cancer treatments.